The era of one-size-fits-all medicine will eventually be history; after all it is no news that drugs and treatments do not work the same for everyone. For patients with nonsmall cell lung cancer (NSCLC), a lung cancer that kills approximately 1 million people annually, the treatment currently available is basically the same for all patients, despite the fact that some patients may respond to treatment while others may not. New biological markers and prognostic tools are urgently needed to help doctors decide on the best course of action for each NSCLC patient. It now appears that this reality is not years away, at least for NSCLC treatment.
Currently, NSCL prognosis is made based on patient's general performance and tumor staging. Still, doctors do not know which patients with NSCLC may survive for only 10 months and which for 5 years. Now, a study published ahead of print in the journal Cancer ("CFL1 expression levels as a prognostic and drug resistance marker in nonsmall cell lung cancer", DOI 10.1002/cncr.25125) presents strong evidence that a protein called cofilin (CFL1) may help doctors in determining patient prognosis and in identifying those in need of a more aggressive treatment. The study also indicates that based on this protein, doctors may decide which drugs to use, and which to avoid, when treating NSCL patients. The possibility of doctors knowing before prescription which drugs are likely to work best for each patient represents a great advance in cancer treatment.
The group led by Dr. Fábio Klamt, a researcher at the Department of Biochemistry at the Federal University of Rio Grande do Sul, Brazil found that cofilin levels can be used to indicate which patients in the early stages of the disease have a good prognosis and which do not. When studying a large collection of NSCL cancer samples, the researchers found that the biopsies in which high levels of cofilin were found were from patients who had survived for shorter periods than those from patients with lower expression of the protein.
Besides the correlation found between cofilin and patient survival, the group also investigated whether cofilin levels could provide any clues on tumor aggressiveness. According to Dr. Klamt, "cofilin is a protein associated with cell mobility. We know that poor prognosis correlates with the ability of cells to move to generate metastasis. Thus, it seemed only reasonable that cells with lower levels of this protein would be less aggressive while higher levels would provide a more aggressive behavior." Indeed, the group tested six human cell lines of 3 major types of NSCLC and found that the types with higher levels of cofilin presented a greater potential to invade other sites in the body, which indicates a more aggressive behavior. "For patients," explains Dr. Klamt, "this finding indicates that lower levels of cofilin translate into lower chances to develop metastasis, which ultimately leads to a better prognosis."
The group also found that high levels of cofilin correlate with resistance to certain anticancer drugs, especially cisplatin and carboplatin, which have long been used for treating NSCLC. Cisplatin-based chemotherapy is the standard first-line treatment for patients at an early stage and with good performance. Nevertheless, only some will respond to this treatment. Now cofilin levels may be used to distinguish between responders and non-responders. This new finding may have great impact on survival rates, as potential non-responders may benefit from different treatment options that would not be available otherwise.
The study was funded by the Brazilian Science and Technology Ministry/National Counsel of Technological and Scientific Development (MCT/CNPq), the MCT/CNPq National Institutes for Translational Medicine (INCT-TM), and the National Cancer Institute, National Institutes of Health (USA).
A patent concerning CFL1 expression levels as a prognostic biomarker for NSCLC has been recently filed with the Brazilian Patent Office (Instituto Nacional da Propriedade Industrial – INPI) under the number # PI0802917-2
Other researchers working on the study include Mauro Antonio Alves Castro, Felipe Dal-Pizzol, Stephanie Zdanov, Marcio Soares, Carolina Beatriz Müller, Fernanda Martins Lopes, Alfeu Zanotto-Filho, Marilda da Cruz Fernandes, Jose Claudio Fonseca Moreira, and Emily Shacter.
Marcia Triunfol | EurekAlert!
Further reports about: > CFL1 > CFL1 expression levels > Carboplatin > Cisplatin > Klamt > MCT/CNPq > NSCL > NSCLC > aggressive behavior > anticancer drugs > biological marker > biological markers > cancer drug > cell lung cancer > early stage > lung cancer > prognostic tools > small cell lung cancer
NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University
How to turn white fat brown
07.12.2016 | University of Pennsylvania School of Medicine
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
07.12.2016 | Health and Medicine
07.12.2016 | Life Sciences
07.12.2016 | Health and Medicine